Flash | 24 Jun 2026 11:01:33 ET │ 11 pages Hypera SA (HYPE3.SA) Semaglutide race is on (part II) CITI'S TAKE CMED published this morning the official filing for Hypera's semaglutide- based injectable pen, Semavy. While the product remains pending sanitary approval, the pricing submission marks an important step toward full regulatory clearance and suggests that final approval could be approaching in the near term. Although timing and pricing/economic details remain unclear, the development may help surface ...